

## Environmental and Social Data Sheet

### Overview

Project Name:	ALK-ABELLO ANTI-ALLERGY TREATMENT RDI
Project Number:	2016-0046
Country:	Denmark
Project Description:	Financing of ALK-Abello's research and development activities into allergic diseases.
EIA required:	No
Project included in Carbon Footprint Exercise <sup>1</sup> :	No

### Environmental and Social Assessment

#### Environmental Assessment

ALK-ABELLO has a sound Safety Health and Environment (SHE) policy including commitments to comply with legal requirements, prevent pollution, continual improvement, regular audits and annual report of its SHE performance. R&D facilities and practices are in compliance with EU relevant regulation and the promoter maintains adequate internal procedures and management practices.

#### Other Environmental and Social Aspects

Allergy is a debilitating condition for persons affected who face a relentless loss in productivity and impairment of their quality of life. Dealing with these patients imposes significant costs on national health systems. The project is focusing on the development of new anti-allergy treatments that would potentially have significant benefits to the society.

The promoter has adequate policy and procedures in place to properly manage clinical trials in the different region of the world also in accordance with the EU regulation 536/2014 in Europe. The use of animal testing is minimised and in line with the EU directive 2010/63/EU.

### Conclusions and Recommendations

The Research and Development activities are not specifically mentioned in the EIA directive and are therefore not subject to mandatory Environmental Impact Assessment. Furthermore, the project concerns investments in research and development that will be carried out in existing facilities mainly at the promoter central R&D site in Hørsholm (Denmark), without changing their already authorised scope. An Environmental Impact Assessment (EIA) is therefore not required under Directive 2011/92/EU as amended.

If successful the project will help promoting the diffusion of treatments against allergies which are affecting some 150 million people in Europe (the most common chronic disease). The project presents high potential health and social benefits for the society; it is therefore acceptable for financing by the Bank.

PJ/SQM/ECSO 15.10.15

<sup>1</sup> Only projects that meet the scope of the Pilot Exercise, as defined in the EIB draft Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: above 100,000 tons CO<sub>2</sub>e/year absolute (gross) or 20,000 tons CO<sub>2</sub>e/year relative (net) – both increases and savings.